Industry News (Clinical Trial)

Phase II Trial Seeks Patients with Fibrocystic Breast Disease

Published in Women's Health Weekly, October 19th, 1998

Symbollon Corporation and Clinical Studies, Ltd. (CSL), a wholly-owned subsidiary of PhyMatrix Corp., announced that they have begun recruiting patients for a Phase II clinical trial investigating the safety and efficacy of IoGen^TM, a novel drug compound used in the treatment of symptoms associated with moderate and severe fibrocystic breast disease (FBD).

The multicenter study represents the first human clinical trial for IoGen. Published scientific literature describes a relationship between iodine and healthy breast tissue, according to CSL. IoGen thus may have applications in the treatment of FBD, one of the most common nonmalignant breast disorders of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (1998-10-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry